Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend

Rhea-AI Summary

Cryo-Cell International (NYSE: CCEL), the world's first private cord blood bank, has announced the initiation of a regular quarterly cash dividend of $0.25 per share. The dividend will be paid on November 29, 2024, to shareholders of record as of November 15, 2024. The Board of Directors will evaluate the dividend policy regularly, considering factors such as earnings, cash flows, and capital requirements. The company's Chairman and Co-CEO David Portnoy emphasized this as a significant step in delivering shareholder value while continuing to evaluate strategic alternatives.

Positive

• Introduction of quarterly dividend payment of $0.25 per share
• Demonstrates financial stability and commitment to shareholder returns

Negative

• Future dividend payments not guaranteed and may be decreased based on company performance
• Dividend payments could limit capital available for business growth and strategic initiatives

OLDSMAR, Fla.--(BUSINESS WIRE)-- Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 2024. The Board of Directors plans to evaluate the dividend policy on a regular basis, considering the Company’s earnings, cash flows, and alternative uses of and access to capital that may arise. Depending on these factors, future dividend payments may be increased or decreased and there is no assurance that future dividends will be paid.

Cryo-Cell’s Chairman of the Board and Co-CEO, David Portnoy, stated, “This marks a significant step in the Company’s strategy to deliver value to its shareholders and does not detract from the ongoing evaluation of strategic alternatives for the Company.”

About Cryo-Cell International, Inc.

Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. ‎More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with ‎their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell ‎International has a public banking program in partnership with Duke University. Cryo-Cell’s ‎public bank has provided cord blood for more than 600 transplantations and operates cord ‎blood donation sites across the U.S in prominent hospitals such as Cedars–Sinai Hospital in ‎Los Angeles. Cryo-Cell’s facility is FDA registered, cGMP-/cGTP-‎compliant and licensed in all states requiring licensure. Besides being AABB accredited as a ‎cord blood facility, Cryo-Cell was also the first U.S. (for private use only) cord blood bank to ‎receive FACT accreditation for adhering to the most stringent cord blood quality standards ‎set by any internationally recognized, independent accrediting organization. Cryo-Cell has ‎the exclusive rights ‎to PrepaCyte-CB, the industry’s most advanced cord blood processing ‎technology.‎

Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. ‎

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the complexities, uncertainties, required consents and timing related to the potential spinoff of Celle Corp., the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-Q filed on October 15, 2024.

This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030287690/en/

Irene Smith

813-749-2102

Ismith@cryo-cell.com

Source: Cryo-Cell International, Inc.

FAQ

What is the dividend amount announced by Cryo-Cell (CCEL)?

Cryo-Cell (CCEL) announced a quarterly cash dividend of $0.25 per share of common stock.

When will Cryo-Cell (CCEL) pay its first quarterly dividend?

Cryo-Cell (CCEL) will pay the dividend on November 29, 2024, to shareholders of record as of November 15, 2024.

Is Cryo-Cell's (CCEL) quarterly dividend guaranteed for future payments?

No, future dividend payments are not guaranteed and may be increased or decreased based on factors including earnings, cash flows, and capital requirements.

What is the record date for Cryo-Cell's (CCEL) first quarterly dividend?

The record date for Cryo-Cell's (CCEL) first quarterly dividend is November 15, 2024.